PSRC Abstract Supplement performed using chi-squared tests and one-way ANOVA. ROC curves were used to evaluate the ability of intra-operative tissue oxygenation in predicting clinical flap necrosis.
PURPOSE:
Insulin-like growth factor 1 (IGF-1) is a potent mitogen with well-described trophic and anti-apoptotic effects on neurons, myocytes, and Schwann cells (SCs) . Local delivery of IGF-1 is limited by its short half-life. The aims of this study are to (1) encapsulate IGF-1 into biodegradable nanoparticles (NPs) that stabilize IGF-1 in its bioactive state and enable sustained release at target tissue sites that persist throughout the regenerative period; and (2) assess the efficacy of locally delivered IGF-1 NPs in augmenting axonal regeneration while also reducing denervation-induced muscle atrophy and SC senescence to thereby improve functional recovery following nerve injury.
METHODS:
(1) NP Fabrication: IGF-1 was first complexed with dextran sulfate to create hydrophobic ionic paired (HIP) complexes, which were then encapsulated in biodegradable NPs. Varying ratios of HIP:polymer were evaluated to maximize loading efficiency and release kinetics. In vitro NP release kinetics were evaluated and mitogenic activity of released IGF-1 was compared to native IGF-1. (2) The effects of locally-delivered IGF-1 NPs on denervated muscle and Schwann cells were assessed in a rat median nerve transection-without-repair model. The effects of IGF-1 NPs on axonal regeneration, muscle atrophy and reinnervation, and recovery of forepaw function were assessed in a model in which chronic denervation is induced prior to nerve repair; functional recovery was assessed weekly with stimulated grip strength testing prior to sacrifice at 15 weeks for histologic analyses.
RESULTS:
(1) Fabrication of uniform NPs with an encapsulation efficiency of 83.2% was achieved. NPs composed of 1:5 PEG 5k -PCL 40k yielded optimal release of IGF-1. Near-zero-order release of IGF-1 can be achieved for at least 70 days and released IGF-1 exhibits comparable bioactivity to native IGF-1. (2) IGF-1 treated animals recovered significantly more forceful grip strength compared to negative controls. IGF-1 NP treatment limits muscle atrophy during periods of denervation compared to negative controls (620 vs. 340μm 2 , respectively; p <0.05).
CONCLUSION:
Encapsulation of bioactive IGF-1 with sustained release for over 70 days was achieved. IGF-1 NP treatment in vivo limits muscle atrophy during denervation and improves functional recovery of forelimb grip strength. PURPOSE: Secondary lymphedema is a debilitating disease characterized by chronic soft tissue swelling. While there is still no cure for lymphedema, we have shown that 9-cisRetinoic acid (9-cisRA) promotes lymphangiogenesis and reduces postsurgical lymphedema in vivo. Despite the resulting efficacy, little is known about the signaling pathway of 9-cisRA in this context. 9-cisRA is thought to induce its target gene responses by binding to and activating nuclear retinoid X receptors (RXRs). The aim of this study was to determine whether RXR signaling is necessary for 9-cis-RA efficacy using lymphatic endothelial cell specific conditional deletion mutant mice.
METHODS: Tail model of lymphedema was performed on transgenic Prox1-CreER
T2 RXRα fl/fl mice and an agematched control group. Superficial lymphatic vessels were severed by a 5-mm circumferential excision 2-cm distal from the tail base. The animals were treated with 9-cisRA once daily for 40 days. The distal part of the tail was imaged weekly postoperatively and tail volumes were calculated using the truncated cone formula. Tail samples 1-cm distal to the wound edge were collected and histologically analyzed to assess soft tissue thickness. 
RESULTS:

CONCLUSION:
Functional RXRαin lymphatic endothelial cells is necessary for 9-cisRA to reduce postsurgical lymphedema. These detailed mechanistic studies support further translation of 9-cisRA for safe clinical use in the prevention of lymphedema in humans.
